Lamond David
SEC CIK 1770790 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | Dir | 2.32M | $601.5K | — | 7 | 2022-05-19 | 2023-12-12 |
Most active insiders at QNCX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Benatti Luca | Dir | — | $173.5K |
| 2 | Hannah Brendan | COO, CCO, CBO | — | — |
| 3 | Thye Dirk | CEO, CMO, Dir | — | — |
Lamond David made no open-market trades at QNCX in the last 12 months.
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-12-14 | 2023-12-12+ | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | P - Purchase | $1.02 | +45.6K | 2.32M | +2% | +$46.5K |
| 2023-12-14 | 2023-12-12 | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | P - Purchase | $1.02 | +22.3K | 2.30M | +1.0% | +$22.8K | |
| MI | 2023-12-07 | 2023-12-05+ | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | P - Purchase | $1.01 | +57.4K | 2.28M | +3% | +$58.1K |
| MI | 2023-12-01 | 2023-11-29+ | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | P - Purchase | $0.94 | +43.1K | 2.19M | +2% | +$40.5K |
| MI | 2023-08-31 | 2023-08-30+ | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | P - Purchase | $1.31 | +82.1K | 2.14M | +4% | +$107.9K |
| MI | 2023-08-17 | 2023-08-15+ | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | P - Purchase | $1.30 | +250.0K | 2.10M | +14% | +$325.7K |
| I | 2022-05-23 | 2022-05-19 | QNCX | Quince Therapeutics, Inc. | Lamond David | Dir | A - Grant | — | +200.0K | 1.73M | +13% | — |
Purchase Sale Sale after option exercise All abbreviations